Drug delays type 1 diabetes in people at high risk: Study
PTI, Jun 10, 2019, 4:29 PM IST
Washington: In a first, scientists have developed a treatment that can delay type 1 diabetes by two or more years among people who are at high risk.
The research, published in the New England Journal of Medicine, involved treatment with an anti-CD3 monoclonal antibody (teplizumab).
Participants were randomly assigned to either the treatment group, which received a 14-day course of teplizumab, or the control group, which received a placebo.
All participants received glucose tolerance tests regularly until the study was completed, or until they developed clinical type 1 diabetes — whichever came first.
During the trial, 72 per cent of people in the control group developed clinical diabetes, compared to only 43 per cent of the teplizumab group.
The median time for people in the control group to develop clinical diabetes was just over 24 months, while those who developed clinical diabetes in the treatment group had a median time of 48 months before progressing to diagnosis.
Type 1 diabetes develops when the immune system’s T cells mistakenly destroy the body’s own insulin-producing beta cells. Insulin is needed to convert glucose into energy.Teplizumab targets T cells to lessen the destruction of beta cells.
“Previous clinical research found that teplizumab effectively slows the loss of beta cells in people with recent onset clinical type 1 diabetes, but the drug had never been tested in people who did not have clinical disease,” said Kevan C Herold, of Yale University.
“We wanted to see whether early intervention would have a benefit for people who are at high risk but do not yet have symptoms of type 1 diabetes,” Herold.
The effects of the drug were greatest in the first year after it was given, when 41 per cent of participants developed clinical diabetes, mainly in the placebo group.
Many factors, including age, could have contributed to the ability of teplizumab to delay clinical disease, since at-risk children and adolescents are known to progress to type 1 diabetes faster than adults.
Faster progression of type 1 diabetes is associated with a highly active immune system, which may explain the impact of immune system-modulating drugs like teplizumab.
Other data collected from the trial may help researchers to understand why certain people responded to treatment. Participants who responded to teplizumab tended to have certain autoantibodies and other immune system characteristics.
The research team also cautioned that the study had limitations, including the small number of participants, their lack of ethnic diversity, and that all participants were relatives of people with type 1 diabetes, potentially limiting the ability to translate the study broadly.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Low back pain, depression, headaches main causes of poor health: Study
Surgical options for Parkinson’s disease
Breast cancer to cause a million deaths a year by 2040: Lancet commission
Will to resist temptations, achieve goals more trustworthy than using apps, study finds
Govt directs e-commerce firms to remove drinks, beverages from ‘health drinks’ category
MUST WATCH
Latest Additions
2 Indian students killed in Scottish waterfall accident
M’luru: Hotelier approaches consumer court after car filled with diesel instead of petrol
Low back pain, depression, headaches main causes of poor health: Study
Can AI Read Our Minds? And Should We Be Worried About It?
Lok Sabha Elections 2024: Zero voter turnout in 6 Nagaland districts amid shutdown call by ENPO over separate territory demand